Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.

SNYPositive Net Change GSKPositive Net Change MRKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies

The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.

MRKNegative Net Change MRNANegative Net Change ANVSNegative Net Change IMTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant

In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change